Abstract
Background: Cytogenetic studies in clonal plasma cell disorders have mainly been done in whole bone marrow or CD138 + microbead-enriched plasma cells and suggest that recurrent immunoglobulin heavy chain translocations -e.g. t(4;14) -are primary oncogenetic events. The aim of this study is to determine cytogenetic patterns of highly purified aberrant plasma cells (median purity ≥ 98%) in different clonal plasma cell disorders.
Design and Methods:
We analyzed aberrant plasma cells from 208 patients with multiple myeloma (n=148) and monoclonal gammopathy of undetermined significance (n=60) for the presence of del(13q14), del(17p13) and t(14q32) using multicolor interphase fluorescence in situ hybridization. Additionally, analysis of immunoglobulin heavy chain gene arrangements and complementarity determining region 3 sequencing was carried out in a subset of patients and combined multicolor interphase fluorescence in situ hybridization/immunofluorescent protein staining analyses were performed in selected cases to confirm clonality and cytogenetic findings.
Results: At diagnosis, 96% of multiple myeloma versus 77% of monoclonal gammopathy of undetermined significance cases showed at least one cytogenetic alteration and/or hyperdiploidy. The cytogenetic heterogeneity of individual cases reflected coexistence of cytogenetically-defined aberrant plasma cell clones, and led
Introduction
Acquisition of del(13q14), immunoglobulin heavy chain (IGH) translocations at chromosome 14q32 -t(14q32) -and numerical gains of different chromosomes (e.g., trisomies of chromosomes 3, 5, 7 and 9) are considered to be early cytogenetic events in clonal plasma cell disorders (PD), whereas other molecular changes (e.g, MYC dysregulation and RAS mutation) are characteristic of malignant transformation and advanced stages of the disease. 1-3 Despite this, limited and controversial data is currently available about the patterns and the chronological sequence of acquisition of cytogenetic alterations at the intratumoral cell level in multiple myeloma (MM) versus monoclonal gammopathy of undetermined significance (MGUS). [4] [5] [6] [7] [8] [9] This relates to the fact that the majority of studies reported so far, relied on conventional cytogenetics with relatively few metaphases analyzed and/or single color/single chromosome interphase fluorescence in situ hybridization (iFISH) analyses of whole bone marrow (BM) samples or plasma cells (PC) enriched by CD138 + microbeads. 4, 10, 11 Albeit significantly more karyotypic aberrations can be identified in MM and 12 . Normal PC are typically absent or infrequent in MM, but they account for >5% of all BM PC in nearly 90% of MGUS patients, with a mean percentage of <2% of N-PC in MM and of around 65% in MGUS. [13] [14] [15] [16] Moreover, previous studies suggest that CD138 could be rapidly lost by apoptotic PC 17 and a subpopulation of CD138 -PC frequently coexists with the major fraction of CD138 + PC. 18 Finally, the 85%-95% median purity of magnetically enriched CD138 + PC limits detailed evaluation of clonal profiles in cases carrying one or multiple cytogenetic changes, particularly as regards identification of a fraction of non-altered aPC, 19 as also described for other B cell neoplasias. 20 Simultaneous usage of the FISH technique and immunophenotyping (e.g., staining
for CD138 or cytoplasmatic light chains) through the so-called FICTION technique or
May-Grünwald-Giemsa staining has occasionally been described. 21, 22 However, both approaches are limited by the fact that only a low number of PC are analyzed in a cytospin preparation, a BM smear or a formalin-fixed, paraffin-embedded section.
Conversely, flow cytometry allows large scale, high purity sorting (median ≥98%) of N-PC and aPC. 23 To the best of our knowledge, only one cytogenetic study using flow cytometry-sorted aPC has been published so far, but analysis was focused on numerical chromosomal alterations and did not include the prognostically informative IGH gene rearrangements. 24 In the present study we investigated the intratumoral patterns of cytogenetic alterations in a large series of MM and MGUS patients, using multicolor iFISH analysis of highly purified flow cytometry-sorted aPC. Further analysis of IGH gene arrangements and complementarity determining region 3 (CDR3) sequencing was carried out in a subset of patients and the simultaneous application of iFISH and immunofluorescent protein stainings (FICTION or immunoFISH technique) was performed in selected cases to confirm clonality and cytogenetic findings. Overall, the cytogenetic heterogeneity of aPC from individual patients reflected coexistence of cytogenetically-defined aPC clones; this suggests that acquisition of cytogenetic alterations occurs stepwise within the BM aPC compartment of individual PD patients; noteworthy, different but related cytogenetic patterns were frequently found in MM versus MGUS. Interestingly, in individual MGUS cases, and to a lesser extent also in MM, a significant proportion of aPC carrying an IGH translocation -including recurrent cytogenetic alterations such as t(11;14) -coexists at the intratumoral cell level with aPC lacking these alterations.
Design and methods

Patients
Patients with newly diagnosed MM (n=148) and MGUS (n=60) were included in this study; three MM patients underwent assessment of cytogenetic alterations during follow-up at different disease stages. Written informed consent was given by each subject. In order to avoid borderline cases we excluded from the analysis those MGUS patients with ≤5% N-PC (since they are at high risk of progression to MM 15 ) as well as those MM patients with the opposite pattern (>5% N-PC) who have a more indolent course of the disease. 13, 15, 16 IgM MGUS was also specifically excluded from this series of patients. The study was approved by the local ethics committee and conducted in accordance with the declaration of Helsinki protocol.
Multiparameter flow cytometry and sorting of aberrant plasma cells
Immunophenotyping of N-PC and aPC was performed on EDTAanticoagulated, erythrocyte-lysed BM samples with a conventional direct immunofluorescence stain-and-then-lyse technique, as previously described. 16 Percentages of aPC with a distinct cytogenetic alteration were systematically adjusted to the purity of aPC using the following formula: `% of cells with a distinct cytogenetic alteration x 100/% purity of aPC´. The karyotypic patterns of cytogenetic alterations were separately assessed in every case in order to define individual aPC clones based on the percentage of aPC with a distinct cytogenetic alteration using a 15%-threshold as specified below. Only those clones that differed between them in >15% of the aPC, were considered to be cytogenetically different. This criteria (>15% aPC without a specific cytogenetic alteration -e.g. t(14q32) -) was also used in cytogenetically altered cases, to define the presence of an aPC clone lacking the tested cytogenetic alteration. In those few cases with two different cytogenetically altered aPC populations differing by ≤ 15% aPC but only one of them comprising ≥85% of all aPC, the two cell populations were considered to belong to the same (i.e.
initial) clone because of the estimated maximum contamination with N-PC cells in the BM and the variability associated with iFISH spot counting. Karyotypic alterations found in the majority of aPC (≥85%) were considered to be early oncogenetic events, whereas those found only in a fraction of aPC were considered to occur later during disease evolution. Confirmation of parent-progeny relationships and coexistence of multiple clones was achieved by simultaneous hybridization with all involved probes in addition to the hybridizations performed with double stainings documented above, as illustrated in Figure 1 . iFISH slides from cases with t(14q32) were blindly evaluated by two independent expert observers with a high reproducibility (Supplementary Table I ). Of note, none of the N-PC analyzed showed chromosomal alterations for all iFISH probes assayed.
Analysis of DNA ploidy of aberrant plasma cells
Evaluation of flow cytometry DNA ploidy was based on a double staining for nuclear DNA (propidium iodide) and surface PC antigens (anti-CD38 and anti-CD138 monoclonal antibodies), as previously reported in detail. 27, 29 The DNA index was defined as the ratio between the modal channel of the G0-G1 peak of PC and the G0-G1 peak of the remaining residual normal cell populations. Hypodiploidy was defined when the DNA index was ≤ 0.9, hyperdiploidy when it was ≥ 1.08; all other cases with a DNA index >0.9 and <1.08 were classified as being DNA diploid.
FICTION analyses
Briefly, for FICTION analyses (n=4 MM cases) flow cytometry-sorted aPC cells were sequentially washed with phosphate buffered saline (PBS) containing 1% bovine serum albumine (BSA) permeabilized (PBS with 1% BSA + 0.1% TritonX), and washed again (PBS with 1% BSA). Then stainings were performed in parallel with anti-CyIgκ-APC (DAKO, Glostrup, Denmark) and anti-CyIgλ-APCH7 (BD)
antibodies, followed by a modified iFISH protocoll as described above. Stained samples were analyzed using a Confocal Laser Scanning Microscope (TCS SP2, LEICA, Heidelberg, Germany). cytogenetic groups according to the `karyotypic pattern´ based on the presence or absence of del(13q14) and del(17p13) with or without t(14q32) ( Table 2 ).
Analysis of IGH gene rearrangements and CDR3 sequencing
The at diagnosis, and carried a t(14q32) in a high percentage of aPC (>82%); in all these cases normal iFISH patterns were systematically found within the purified N-PC fraction -<1% nuclei with a t(14q32) -.
Intratumoral patterns of cytogenetic alterations
The presence of ≥2 cytogenetically different clones in aPC from the same patient and sample was more commonly observed in MM (95/148 cases, 64%) than in MGUS (22/60 cases, 37%) (p<0.001) ( Table 3 ). In order to determine the specific potential clonal profiles in MM versus MGUS we investigated whether there were shared profiles between the two patient groups, based on both the presence versus absence of del(13q14), del(17p13) and/or t(14q32) and the presumed chronological sequence of acquisition of these cytogenetic alterations (Table 2) ; for this purpose only MM and MGUS patients with cytogenetic alterations by iFISH for the respective chromosomal regions were included in this part of the analysis. Considering the karyotypic patterns defined by the presence of del(13q14), del(17p13) and t(14q32), 98/110 (89%) patients with MM showed patterns which were also found in MGUS and 24/24 (100%) MGUS cases had patterns found also in MM (p>0.05). Despite this, when the presumed chronological sequence of acquisition of these alterations together with +17p13 was considered, the frequency of shared patterns decreased to 87/119 (73%) in MM but remained 100% among MGUS cases (29/29) (p<0.001; showed that aPC with and without the translocation might coexist in the same patient/sample, whereas all investigated cells expressed only one single light chain type (cyIgκ or cyIgλ) confirming the high purity of flow cytometry-sorted aPC ( Figure   4 ).
Interestingly, in some of the MM cases which were exemplarily evaluated during follow-up at different disease stages, the non-altered aPC clone persisted during disease evolution, even in cases carrying a recurrent IGH translocation such as t(4;14) (Supplementary Table IV) .
DNA ploidy status and immunophenotype of neoplastic plasma cells
The frequency of DNA hyperdiploidy was similar in MM and MGUS (47% versus 45%; Figure 3 ). As expected, presence of t(14q32) was prevailing in nonhyperdiploid versus hyperdiploid cases in both MM (57% versus 25%; p<0.001) and MGUS (30% versus 11%; p>0.05). Del(13q14) was likewise more frequent among non-hyperdiploid versus hyperdiploid cases in MM (63% versus 45%; p=0.03).
Conversely, del(17p13) was found at similar frequencies in hyperdiploid versus nonhyperdiploid MM cases (14% versus 9%; p>0.05). +17p13 was more frequent among hyperdiploid MM (25%) and MGUS (19%) versus non-hyperdiploid cases (5% and 3%; p<0.001 and p=0.08, respectively), while del(14q32)/+14q32 in the absence of t(14q32) showed no significant association with DNA ploidy, neither in MM nor in MGUS (data not shown).
Analysis of IGH gene rearrangements and CDR3 sequencing of aberrant PC.
Analysis of IGH gene rearrangements and CDR3 sequencies of highly purified aPC was performed in 9 exemplarily (2 MGUS and 7 MM) cases; 2 of them had none of the tested cytogenetic alterations and the other 7 showed at least one cytogenetic alteration (Supplementary Table V) . In 2 out of these latter 7 MM cases a fraction of the aPC purified had a recurrent IGH translocation -t(4;14) and t(11;14), respectively -and coexisted with another aPC fraction without it (36% and 23%, of all aPC in cases N. 93759 and 85864; Supplementary Table V) . Hereby, only one unique CDR3 sequence was identified for each sample analyzed, indicating a clonal relationship between the IGH-translocated and non-translocated cases and absence of a significance proportion of contaminating polyclonal N-PC.
Discussion
In the present study virtually all MM and the great majority of MGUS patients showed hyperdiploidy and/or cytogenetic alterations involving chromosomes 13q14, 17p13 and 14q32. Overall, del(13q14), del(17p13) and t(14q32) were identified at significantly greater frequencies among MM versus MGUS cases; conversely the incidence of +17p13 and del(14q32)/+14q32 in the absence of t(14q32) did not differ significantly between both groups of patients. 
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Cytogenetic profiles MM (n=148) MGUS (n=60) I [t(14q32)+, del(13q14)+]
39 (26%)** 2 (3%)** V [t(14q32)-, del(13q14)-, del(17p13)-] 38 (26%)** 36 (60%)** (1) none 29 (20%) 31 (52%) (2) +17p13 9 (6%) 5 (8%)
Results are expressed as number of patients and percentages between brackets. T(4;14) occurred more frequently among group I than group II MM patients (14/39 patients, 36% versus 2/23 patients, 9%, p=0.03), while t(11;14) was more common among group II than group I cases (11/39, 28% versus 14/23 patients, 61%, p=0.02). The 2 MGUS patients in group I showed t(11;14) and `other t(14q32)´, respectively. The median DNA index was significantly (p=0.01) increased in MM versus MGUS patients within group V cases: 1.2 (range: 1.0-1.6) versus 1.1 (range: 1.0-1.7), respectively (no significant differences within the other groups). Abbreviations are explained in Table 1 Table 3 . Number of cytogenetically different clones in the distinct cytogenetic groups of MM versus MGUS patients.
Karyotypic pattern
At least 2 cytogenetically different clones
14/38 (37%)** 6/36 (17%)** Total 95/148 (64%)*** 22/60 (37%)***
Results are expressed as number of cases from the total number of patients in the respective group. Abbreviations are explained in Results are expressed as percentage of aPC from all aPC analyzed as determined by two independent expert observers (separated by /). Each clone encompassed >15% of counted aPC by at least one of the two expert observers. PD, clonal plasma cell disorder; aPC, aberrant plasma cell; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma. † none of the tested cytogenetic alterations identified.
‡ sum of minor clones, each encompassing ≤15% of counted aPC.
§ numbers refer to 
III [t(14q32)-, del(17p13)+]
none → del(14q32) → del(17p13) 1 0 del(13q14) & del(17p13) & del(14q32) 1 0 none → del(13q14) & del(16q23) → del(17p13) & del(14q32) 1 0 IV [t(14q32)-, del(13q14)+, del(17p13)-] del(13q14) 3 1 none → del(13q14) 6 1 del(13q14) & del(14q32) 1 2 del(14q32) → del(13q14) 2 1 none → del(13q14) → del(14q32) 1 0 del(13q14) → del(14q32) → del(14q32) second chromosome 1 0 none → del(13q14) & del(14q32) 2 0 none → A: none, B: del(13q14) → del(14q32) 0 1 none → del(13q14) & del(14q32) → +17p13 1 0 del(13q14) → +17p13 → further del(13q14) & ++17p13 1 0 V [t(14q32)-, del(13q14)-, del(17p)-]
Results are expressed as number of cases. Abbreviations are explained in Supplementary Table I. 1 defined as a deletion or a gain of 14q32 (IGH) or of the respective partner region (FGFR3, CCND1 or MAF) in cases already carrying a translocation or numeric alteration of the IGH gene in a previous clone.
2 del(14q32) in the absence of t(14q32) (including deletion potentially associated with t(14q32) but absence of t(4;14), t(11;14) and t(14;16)). 3 >15% of aPC without any of the cytogenetic alteration tested (`diploid´). 4 two aPC populations with different cytogenetic evolution patterns sorted by flow cytometry. +: cytogenetic alteration present. -: cytogenetic alteration absent. →: sequential acquisition. &: simultaneous acquisition. 
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Analysis of IGH gene rearrangements and CDR3 sequencing
Highly purified BM aPC were lysed using the REDExtract-N-Amp Blood PCR Kit (Sigma, St. 
Louis
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